NOX4 and Related Biomarkers in ADPKD
To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).
| Condition(s) | Autosomal Dominant Polycystic Kidney Disease |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD). |
| Who can participate | Inclusion Criteria: * ADPKD (based on Ravine et al. criteria) * Class 1 A-E according to imaging classification * Male and female subjects 15 - 40 years of age * Estimated GFR\> 70 mL/min/1.73 m2 (CKD-EPI) * Ability to provide written, informed consent Exclusion Criteria: * Class 2 according to imaging classification * Concomitant systemic disease affecting the kidney * Diabetes mellitus * Predicted urine protein excretion in \>1 g/24 hrs * Use of antioxidants i.e. vitamins, Nrf2 activators * Abnormal urinalysis |
| Ages | 15 Years to 40 Years |
| Sex | All |
| Lead sponsor | Mayo Clinic |
| Locations | Rochester, Minnesota, United States |
| Start date | 2020-07-21 |
| NCT ID | NCT04630613 |
| Official listing | https://clinicaltrials.gov/study/NCT04630613 |